Castle Biosciences shares are trading higher after BTIG maintained a Buy rating on the stock and raised its price target from $35 to $40.
Portfolio Pulse from Benzinga Newsdesk
Castle Biosciences shares rose after BTIG maintained a Buy rating and increased the price target from $35 to $40.
October 14, 2024 | 3:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Castle Biosciences shares are trading higher following BTIG's decision to maintain a Buy rating and raise the price target from $35 to $40.
The increase in price target and maintained Buy rating by BTIG is a positive signal for investors, likely leading to increased investor confidence and a short-term rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100